New drug targets Hard-to-Treat BRAF cancers in Mid-Stage trial
Disease control
Recruiting now
This study tests a drug called FORE8394 (plixorafenib) in people aged 10 and older with advanced solid tumors or brain tumors that have specific BRAF gene changes. The goal is to see if the drug can shrink tumors and control the disease. About 254 participants will take the drug …
Phase: PHASE2 • Sponsor: Fore Biotherapeutics • Aim: Disease control
Last updated May 11, 2026 20:39 UTC